AEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Received FDA Type 2b feedback providing greater clarity on AEON's integrated biosimilar development strategy combining comparative analytical assessment, human pharmacodynamic studies, and a substantial body of existing comparative clinical evidence -- Submitted IND for comparative CMAP pharmacod…